Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/e5ddd69b-3c28-4c0d-8247-541f77cd2d69/

NUTX

Nutex Health Inc
Chart
162.98 USD
Latest Week 2026-07-17
Snapshot 2026-07-19 · 0.6w · Fresh
0.98
OS Score
91.0%
Value
98.0%
Quality
80.0%
Momentum
#37.00000000
TV Rank
7/9
F-Score
0.944
QV
Strategy Eligibility
12 of 23 passing
OS Composite
OS 0.980
Trending Value
#37
Quality × Value
QV 0.944
🏛
Cornerstone Value
🌿
Cornerstone Growth
💎
Deep Value
P/E 11.6
VC2 Cheapest
VC2 9
📐
EBITDA/EV
21.5%
Veiled Value
Piotroski Bargains
F7
🔬
Quality Compounders
📈
Consistent Earners
🌱
GARP
Rev +41%
🔄
Shareholder Yield
7.8%
💰
High Yield
Div 7.3%
🚀
Momentum Leaders
Market Leaders
Tiny Titans
🔍
Small Cap Value
Val 91%
🛡
Low Volatility
🏷
Sector Cheapest
🧠
Capital Allocators
CAQ 1.00
Risk-Adj Momentum
V
Value Analysis
Cheapness relative to fundamentals
91.0%ile
P/E
11.6×
P/S
1.3×
P/B
3.2×
E/P
0.2025
FCF Yield
0.203
EBITDA/EV
0.215
SH Yield
0.078
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
11.00000000
/100 — 1=cheapest
VC2 (Trending Value)
9.00000000
/100
VC3 (Buyback)
10.00000000
/100
P/E of 11.6x places this firmly in deep value territory. FCF yield of 20.3% is strong — the business generates significant free cash relative to price. VC2 score of 9.00000000/100 puts this in the cheapest decile of the universe — prime Trending Value territory.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
98.0%ile
ROE
0.278
ROA
0.101
Net Margin
0.110
Op Margin
0.313
GPA
0.436
D/E
1.49
Current
3.14
F-Score
7/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.410
Earn Growth
0.435
Stability
1.487
lower=better
Accruals
-0.184
lower=better
5yr Consist
No
ROE of 28% is exceptional.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
80.0%ile
6M Return
6.7%
12M Return
43.2%
12-1 Mom
32.2%
Risk-Adj
0.33
Vol 252d
97.9%
Vol 60d
225.8%
↑ Expanding
Max DD 12M
-52.3%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 32% is very strong — a clear uptrend. Near-term vol (226%) is expanding vs long-term (98%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.98
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
Sector Context
Healthcare · 500 peers
Sector Value %ile
95.6%
Sector Quality %ile
99.4%
P/E z-score
-0.29
P/B z-score
-0.17
Sector Avg OS
64.0%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 91.0% 98.0%
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 96.0%
CGEN Compugen 98.0% 89.0% 96.0% 82.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 90.0% 93.0% 93.0%
FBIO Fortress Biotech Inc 98.0% 98.0% 84.0% 88.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 84.0%
MD Mednax Inc 97.0% 85.0% 84.0% 93.0%
PBYI Puma Biotechnology Inc 96.0% 76.0% 97.0% 96.0%
Factor Interactions
Value + Quality Intersection
Top-tier on both cheapness (91th) and quality (98th) — the O'Shaughnessy sweet spot, historically the strongest long-term combination.
Trending Value Signal
Cheap (91th value) with strong momentum (80th). The market is starting to recognise the value.
Growth at Reasonable Price
Revenue growing 41% with P/E of 12×. Growth isn't fully priced in.
Strong Capital Return
Shareholder yield 7.8% backed by 20.3% FCF yield. Returns are well-funded.
Hot but Volatile
Strong momentum (80th) but high volatility (98%). Momentum could reverse sharply.
Volatility Expanding
60-day vol (226%) significantly exceeds 252-day (98%). Near-term risk is elevated.
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
A
91.4% avg (7 factors)
Quality
A
79.1% avg (8 factors)
Momentum
C
59.2% avg (4 factors)
Risk
F
0.0% avg (1 factors)
This stock sits in the O'Shaughnessy sweet spot — cheap AND high quality. Historically, this combination has generated the strongest long-term returns. Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends7 snapshots
Factor Persistence7 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.980—7
Value %ile0.910—7
Quality %ile0.980—7
Momentum %ile0.800—3
F-Score7.000—7
Confidence0.969—7
Volatility0.979—7
Value Lens2021-07-20 → 2026-07-19
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
11.64
Earnings Yield (E/P)
0.2025
Price / Sales
1.27
Price / Book
3.24
Price / Cash Flow
4.11
FCF Yield
20.3%
EBITDA / EV
21.5%
Sales Yield (1/P·S)
0.6475
Shareholder Yield
Div + net buyback / mktcap
7.8%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
27.8%
Return on Assets
10.1%
Net Margin
11.0%
Operating Margin
31.3%
Gross Profit / Assets
Novy-Marx GPA
43.6%
Debt / Equity
1.49
Current Ratio
3.14
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.184
External Financing
Net issuance — lower=better
0.005
MomentumPrice trend strength over different horizons
6M Return
6.7%
12M Return
43.2%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
32.2%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.33
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
41.0%
Earnings Growth (YoY)
43.5%
Earnings Stability (CV)
Lower = more stable
1.487
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
7
Dividend Yield
7.3%
Buyback Yield
0.4%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
11
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
9
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
10
Trending Value Rank
1=best. Top VC2 decile by 6M momentum
37
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity